PharmaCyte Biotech(PMCB)
$0.40+-0.00 (+11.67%)
PMCB
PharmaCyte Biotech financials statements
$0.40
At close:+-0.00 (+11.67%)
PharmaCyte Biotech (PMCB) Ratios
266 Followers
PharmaCyte Biotech Ratios
PMCB's free cash flow for Q1 2027 was $-780.89K. For the 2027 fiscal year, PMCB's free cash flow was increased by $0.00 and operating cash flow was $-780.89K. See a summary of the company’s cash flow.
| Ratios | Apr 26 | Apr 25 | Apr 24 | Apr 23 | Apr 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 |
| Quick Ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 |
| Cash Ratio | 22.51 | 5.21 | 6.76 | 115.99 | 121.24 |
| Solvency Ratio | -1.65 | 9.35 | 0.34 | 3.65 | -6.02 |
| Operating Cash Flow Ratio | -6.24 | -1.02 | -0.29 | -6.47 | -5.85 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 25.65M | $ 19.10M | $ 30.05M | $ 67.56M | $ 84.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.06 | 1.52 | 1.01 | 1.01 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -8328.09 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -8628.68 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 3.51 | 3.47 | -7.32 | 15.76 | 20.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 283.42% | -700.25% | -5.12% | 66.86% | 96.52% |
| Return on Assets (ROA) | -41.55% | 55.57% | 0.56% | -5.89% | -4.68% |
| Return on Equity (ROE) | -58.34% | 59.08% | 0.84% | -5.94% | -4.71% |
| Return on Capital Employed (ROCE) | -14.92% | -8.38% | -12.42% | -8.88% | -4.88% |
| Return on Invested Capital (ROIC) | -14.92% | -8.38% | -12.42% | -8.88% | -4.88% |
| Return on Tangible Assets | -41.55% | 57.17% | 0.57% | -6.19% | -4.87% |
| Earnings Yield | -383.68% | 337.30% | 1.64% | -7.58% | -11.72% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.73 | -0.41 | -0.22 | -0.19 | -0.27 |
| Free Cash Flow Per Share | -0.73 | -0.41 | -0.22 | -0.19 | -0.27 |
| Dividend Paid and CapEx Coverage Ratio | -20.95 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -101.78% | -32.77% | -10.59% | -6.67% | -11.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.26 | 0.39 | 60.86 | -13.19 | -8.53 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.15 | 0.18 | 0.51 | 0.78 | 0.40 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.98 | -3.05 | -9.44 | -15.00 | -8.78 |
| Price-to-Operating Cash Flow Ratio | -0.98 | -3.05 | -9.44 | -15.00 | -8.78 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.00 | 0.08 | 0.71 | 0.10 |
| Enterprise Value Multiple | 2.55 | 1.39 | -4.36 | 2.58 | 11.61 |
| Enterprise Value | -13.54M | -6.08M | -29.87M | -11.13M | -49.23M |
| EV to EBITDA | 2.55 | 1.39 | -4.36 | 2.58 | 11.61 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 2.63 | 2.04 | 13.88 | 2.93 | 11.96 |
| EV to Operating Cash Flow | 2.63 | 2.04 | 13.88 | 2.93 | 11.96 |
| Tangible Book Value Per Share | 4.99 | 6.87 | 3.96 | 3.55 | 5.56 |
| Shareholders’ Equity Per Share | 4.75 | 7.08 | 4.12 | 3.73 | 5.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.77 | 4.18 | 0.03 | -0.22 | -0.27 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 3.66 | -7.00 | 1.00 | 0.67 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.27 | -0.10 | -6.45 | 0.88 | 0.97 |
Currency in USD
